Pyxis Oncology Inc (PYXS)

Currency in USD
1.070
+0.020(+1.90%)
Closed·
After Hours
1.061-0.009(-0.88%)
·
PYXS Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 12 days
PYXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.0341.090
52 wk Range
0.8335.390
Key Statistics
Prev. Close
1.05
Open
1.06
Day's Range
1.034-1.09
52 wk Range
0.833-5.39
Volume
142.38K
Average Volume (3m)
497.75K
1-Year Change
-68.84%
Book Value / Share
1.67
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PYXS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.200
Upside
+479.44%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

Pyxis Oncology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Pyxis Oncology Inc Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Pyxis Oncology Inc SWOT Analysis


ADC Innovation
Pyxis Oncology's novel antibody-drug conjugate technology shows promise in early trials, demonstrating efficacy across multiple tumor types
Clinical Progress
Explore PYX-201's development, showcasing a favorable safety profile and potential advantages over existing ADCs in the competitive oncology landscape
Market Potential
Analyst price targets range from $7 to $13, suggesting significant upside potential if upcoming data readouts prove successful
Strategic Outlook
Delve into Pyxis's future prospects, balancing its innovative approach against financial constraints and intense market competition in cancer therapeutics
Read full SWOT analysis

Compare PYXS to Peers and Sector

Metrics to compare
PYXS
Peers
Sector
Relationship
P/E Ratio
−0.7x−4.7x−0.5x
PEG Ratio
0.04−0.040.00
Price/Book
0.6x4.0x2.6x
Price / LTM Sales
-81.6x3.3x
Upside (Analyst Target)
-174.6%43.5%
Fair Value Upside
Unlock0.1%6.9%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.200
(+479.44% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.35 / -0.33
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PYXS Income Statement

People Also Watch

5.48
REPL
-0.36%
17.96
SRPT
+10.46%
37.39
EXEL
-0.85%
3.410
BTAI
+2.71%
17.195
QBTS
-2.19%

FAQ

What Stock Exchange Does Pyxis Oncology Trade On?

Pyxis Oncology is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Pyxis Oncology?

The stock symbol for Pyxis Oncology is "PYXS."

What Is the Pyxis Oncology Market Cap?

As of today, Pyxis Oncology market cap is 65.05M.

What Is Pyxis Oncology's Earnings Per Share (TTM)?

The Pyxis Oncology EPS (TTM) is -1.56.

When Is the Next Pyxis Oncology Earnings Date?

Pyxis Oncology will release its next earnings report on 18 Aug 2025.

From a Technical Analysis Perspective, Is PYXS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Pyxis Oncology Stock Split?

Pyxis Oncology has split 0 times.

How Many Employees Does Pyxis Oncology Have?

Pyxis Oncology has 44 employees.

What is the current trading status of Pyxis Oncology (PYXS)?

As of 07 Aug 2025, Pyxis Oncology (PYXS) is trading at a price of 1.07, with a previous close of 1.05. The stock has fluctuated within a day range of 1.03 to 1.09, while its 52-week range spans from 0.83 to 5.39.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.